Evaluation of Bodily Pain Associated with Polycystic Ovary Syndrome: A Review of Health-Related Quality of Life and Potential Risk Factors

To review the literature to identify the impact of PCOS on pain perception by specific HRQoL, we searched the literature from PubMed using the terms “SF-36” OR “pain” AND “polycystic ovary syndrome”. The literature was restricted to English and full text. We identified 117 studies and excluded 103 publications because of repetitions and irrelevant or not specific topics. Finally, ten studies using the questionnaire SF-36, one using SF12V2, one using semi-structured review, and two original studies matched the topic and were collected in the review ( Table 1 ). Multiple studies have used the SF-36 to evaluate women with PCOS and identified the involvement of pain perception in PCOS symptoms. In 2003, Elsenbruch et al. completed the first quantitative HRQoL study in Germany; it examined how PCOS affected the bodily pain perception of women with PCOS and reported low SF-36 scores for bodily pain [ 16 ]. Their results revealed that patients with PCOS have a decreased HRQoL and that bodily pain is a major domain. Similar results were published in 2005 by Hahn et al., which were the product of an SF-36-based study of women with PCOS in Germany. Their data revealed that in addition to obesity and hirsutism, bodily pain was another key disturbance that reduced the physical quality of life of patients with PCOS [ 17 ]. An SF-36 survey of female participants with PCOS in Poland was conducted to evaluate an HRQoL program [ 14 ]. Its findings also indicated that PCOS significantly influences pain perception; specifically, patients with PCOS scored lower for pain relative to healthy controls and exhibited less favorable results for other dimensions pertaining to physical and mental quality of life [ 19 ]. Notably, the 3 aforementioned studies all reported decreased sexual satisfaction among patients with PCOS, which may be attributable to the changes in physical appearance resulting from conditions such as obesity and hirsutism [ 16 , 17 ]. Further research is required to clarify whether bodily pain impairs sexual intercourse in patients with PCOS. In 2011, Li et al. conducted a meta-analysis examining the application of the SF-36 for evaluating the HRQoL of patients with PCOS; specifically, 5 studies that enrolled a total of 423 patients with PCOS and 285 healthy controls from Germany and China were examined in this meta-analysis. The results indicated that women with PCOS scored lower for all SF-36 dimensions relative to controls. For the pain domain of the SF-36, pain perception is notably greater among patients with PCOS symptoms, and patients with PCOS score significantly lower for this domain relative to controls [ 16 , 17 , 19 , 21 ]. In 2021, Moran-Sanchez et al. conducted a case–control study in Spain and enrolled 156 patients with PCOS and 117 age-matched healthy controls [ 25 ]. They used the Revised Life Orientation Test questionnaire to evaluate the level of optimism of patients with PCOS. A shorter pain evaluation questionnaire, specifically a modified version of the SF-36 named the SF12-V2, was administered to the participants of that study. They discovered that PCOS can impair the optimism of patients with PCOS, and more severe pain perception was also reported by patients with PCOS relative to controls. However, whether pain perception is associated with optimism level was not evaluated in the present study. Obesity is a common symptom of PCOS that is highly associated with hyperandrogenism and IR, and the effect of obesity and PCOS on HRQoL has been investigated. In 2006, Coffey et al. conducted an SF-36 survey in the United Kingdom to evaluate the effect of obesity on pain perception [ 18 ]. They enrolled women with PCOS from an outpatient clinic and healthy age-matched women as controls; they discovered that women with PCOS obtained lower overall SF-36 scores indicative of poorer HRQoL relative to controls and reported that the pain scores of patients with PCOS were 14% lower than those of healthy controls. In particular, they discovered that body mass index (BMI) is a crucial factor that influences pain perception; after adjusting for BMI, the pain perception of the two groups did not differ significantly. In 2010, Alvarez-Blasco et al. conducted a Spain-based SF-36 survey of women with overweight and obesity who intended to lose weight [ 20 ]. Through a comparison of patients with PCOS and their controls, Alvarez-Blasco et al. discovered that the general HRQoL mean scores of the two groups were similar and that their SF-36 pain scores were not significantly different; however, the controls obtained lower scores for a pain-related item in a Nottingham Health Profile HRQoL survey. A study conducted in Spain also reported that hyperandrogenism-related hirsutism and weight gain were the dominant factors that affected the HRQoL of women with infertility. In 2021, Naumova et al. examined patients with both infertility and PCOS, women with tubal factor infertility, and women with male factor infertility to explore the effects of these conditions on HRQoL. They reported that women with both infertility and PCOS obtained lower scores in the general SF-36 assessment and that hirsutism and weight gain were the factors most associated with HRQoL impairment. In their study, the scores for bodily pain were also lower among women with both infertility and PCOS than among those with male factor infertility [ 26 ]. These findings suggest that hyperandrogenism-related obesity is a key factor that influences the HRQoL of patients with PCOS; therefore, the influence of obesity on the pain expression of patients with PCOS warrants further studies. PCOS is a disease with a diverse spectrum of symptoms. In Turkey, Angin et al. enrolled women with both infertility and PCOS and women with only infertility to evaluate the effect of infertility on HRQoL [ 24 ]. Their results indicated that among the women with infertility, PCOS led to lower scores for the pain domain of the SF-36; however, the difference was nonsignificant. In a case–control study conducted in Turkey by Acmaz et al., patients with PCOS were classified according to their complaints into hirsutism, infertility, and obesity groups, and these patients were then evaluated to determine the effect of hirsutism, infertility, and obesity on their HRQoL [ 22 ]. The pain assessment results of their study revealed that patients with PCOS obtained lower pain scores in an SF-36 survey relative to their age-matched healthy controls; the results also revealed that among the patients with PCOS, infertility and hirsutism reduced pain assessment scores to a greater extent than did obesity. These data suggest that infertility and hirsutism are key symptoms that influence the disease pattern of PCOS and the pain perception of patients with PCOS. In 2018, Borghi et al. performed a study in Italy to investigate the relationship of PCOS with psychological disorders and HRQoL by using the Symptom Checklist 90-R (SCL-90-R), SF-36, and State-Trait Anger Expression Inventory-2 (STAXI2). Clinical and biochemical screenings were conducted to collect blood samples obtained through serum biochemical examinations. In total, 30 patients with PCOS and 30 healthy controls were enrolled. The SF-36 questionnaire results indicated that compared to the healthy controls, the patients with PCOS obtained significantly lower scores for the physical functioning and bodily pain items of the SF-36 as well as lower scores for the bodily pain domain [ 23 ]. For the association between phenotypic/biochemical features and psychological distress, the pain perception evaluation revealed that only waist-to-hip ratio and hirsutism significantly influenced the development of psychological disorders in patients with PCOS; that is, hyperandrogenism-related biochemical anomalies were not significant factors. These HRQoL survey findings suggest that although pain perception is more prevalent in patients with PCOS than in healthy controls, the underlying causative factors of either mental or physical effects are still unclear. Obesity may be a key factor involved in pain perception; however, more basic research is required to clarify its underlying effect in this context. In addition to HRQoL survey-based studies on pain, researchers have also adopted pressure pain threshold (PPT) to evaluate patients’ central sensitization level, which is a condition associated with the development and maintenance of chronic pain [ 30 ]. Notably, studies have reported that lean patients with PCOS exhibited a higher PPT relative to their healthy controls [ 28 ] and that this outcome was associated with increased plasma β-endorphin levels in patients with PCOS [ 29 ]. An endogenous opioid analgesic, β-endorphin was reported to influence acute and chronic pain outcomes [ 31 ]. These data suggest that lean patients with PCOS have a higher tolerance to pain expression relative to non-lean patients with PCOS; however, whether patients with both PCOS and obesity exhibit a similar outcome is still unclear. The current literature findings appear to differ from the results obtained through HRQoL questionnaires. Although PPT has been characterized in chronic pain, increased pain expression was also identified in patients with PCOS. The outcomes of PPT in patients with PCOS require more research to clarify, especially for PCOS patients with overweight/obesity.

Several pain subtypes can influence the daily lives of patients with PCOS. Because of the limited research on pain perception in clinical and laboratory settings, the related effects and underlying mechanisms remain unclear. Notably, PCOS manifests as a proinflammatory state in pathophysiology. Studies have reported that the levels of proinflammatory factors (e.g., proinflammatory cytokines and chemokines) were higher in the serum of patients with PCOS than in healthy controls, suggesting the effect of inflammatory status on pain perception [ 32 , 33 , 34 , 35 ]. A moderate increase in circulating C-reactive protein (CRP) level was also detected in patients with PCOS with or without obesity; this finding indicates that patients with PCOS develop low-grade chronic inflammation [ 35 ]. Regidor et al. reported significantly higher levels of proinflammatory lipid mediators in the serum (e.g., arachidonic acid and the arachidonic acid derivatives prostaglandins, leukotrienes, and thromboxanes) in patients with PCOS, suggesting a strong proinflammatory state in patients with PCOS relative to healthy controls [ 32 ]. Studies have reported that inflammation plays a key role in the development and maintenance of several types of pain status in the peripheral and central nervous system [ 36 ] and that the association of chronic systemic inflammation and pain sensitivity is highly involved in the development and maintenance of chronic pain [ 37 , 38 ]. Thus, proinflammatory status can contribute to pain perception in patients with PCOS. Researchers have attributed the association between chronic inflammatory status and PCOS to hyperandrogenism-induced abnormal adiposity and the role of both hyperandrogenism and adipocyte hypertrophy in contributing to insulin resistance [ 33 , 39 , 40 , 41 , 42 ]. The excessive deposition of adipocytes can lead to proinflammation, hypertrophy-induced hypoperfusion, compression, and hypoxia, which can activate intracellular nuclear factor kB and initiate an inflammatory reaction. This activation may further promote the synthesis and release of other inflammation mediators from adipocytes such as members of the interleukin family (IL1-β, IL-6, IL-10, and IL-18), TNF-α, TGF-β, interferon-γ, immune complement factors, sVCAM1, and MCP1. Consequently, macrophage infiltration occurs in adipocyte tissue, maintaining the inflammatory status of the patient with PCOS and impairing their adipose function [ 43 , 44 , 45 ]. In addition, the increased levels of serum-free fatty acids (i.e., ligands of toll-like receptors) in individuals with obesity can trigger immune cell reactivation [ 46 , 47 , 48 ]. Adipokines are cell-signaling proteins released by adipocytes [ 49 ]. Several adipokines with abnormalities due to atypical adipogenesis have been identified in patients with PCOS (e.g., increased levels of leptin, resistin, visfatin, RBP4, and chemerin and decreased levels of apelin, adiponectin, and omentin-1) [ 8 , 50 ]. Studies have reported that adipocytokines play a dual role in pain [ 51 ]. For instance, leptin can function as a proinflammatory adipokine that promotes pain perception [ 52 , 53 ]. Resistin is associated with post-surgery pain, migraine, and osteoarthritis, all of which can alter inflammatory conditions [ 54 , 55 , 56 ]. Visfatin is also involved in pain development in patients with osteoarthritis [ 57 , 58 ]. Studies have reported the analgesic effect of adiponectin in attenuating nociception in animal models of hyperalgesia [ 59 , 60 ]. Apelin can function as a neuropeptide, and it can ameliorate nociception in rats and mediate analgesic effects through serotonin pathways [ 61 , 62 ]. Consequently, the abnormal adipokine levels in patients with PCOS may become a risk factor for worsening pain perception. Proinflammatory cytokines are produced by reactive macrophages, and they contribute to the development of pathological pain. A study reported the involvement of TNF-α and IL-1β in inflammatory and neuropathic hyperalgesia [ 63 ], which results in an abnormal and systematic increase in pain sensitivity. The direct intraplantar injection of TNF-α also caused mechanical and thermal hyperalgesia in experimental animal models [ 64 , 65 , 66 , 67 ]. Further, proinflammatory cytokines and chemokines (e.g., IL-1β, TNF-α, and MCP-1) [ 68 , 69 , 70 , 71 , 72 ] may directly affect the neuronal activity in various classes of neurons in peripheral and central nerves by inciting the activity of nociceptive neurons or dorsal root ganglion (DRG) neurons. IL-6 can modulate astrocytes and microglial gliosis and control the expression of neuronal neuropeptides [ 73 ]; it is also involved in the development of neuropathic pain (including tactile allodynia and thermal hyperalgesia) in experimental rats with nerve injuries [ 74 , 75 ]. IL-1β can be synthesized and released by monocytes, macrophages, fibroblasts, and endothelial cells following inflammatory responses, and IL-1β was also identified in nociceptive DRG neurons [ 76 ]; thus, the intraperitoneal, intracerebroventricular, or intraplantar injection of IL-1β can trigger hyperalgesia [ 65 , 77 ] mechanistically by stimulating the substance P and prostaglandin E2 (PGE2) in neuronal and glial cells [ 78 , 79 ]. For patients with PCOS, obesity is a major symptom that has been reported to be present in approximately 50% to 80% of all patients with PCOS, and IR is a disorder involved in PCOS pathogenesis [ 8 , 80 ]. In one study, obesity- and IR-related syndromes were reported to be associated with chronic low-grade inflammation [ 34 ]. Researchers have revealed that hyperandrogenism is associated with inflammatory response in PCOS and that hyperglycemia (increased blood sugar level) triggered by dietary habits can promote inflammation and IR (e.g., TNF-α, IL-6, ROS, and NF-κB) in PCOS disease models [ 81 , 82 , 83 , 84 ]. Visceral adiposity can manifest across all weight classes in patients with PCOS [ 85 ]; however, the relationship between proinflammatory status and obesity is still being debated. In 2011, Escobar-Morreale et al. conducted a meta-analysis study to evaluate the findings of 31 research articles regarding serum inflammatory markers in patients with PCOS; they discovered that patients with PCOS exhibited significantly higher levels of CRP relative to controls and that this difference remained significant after excluding BMI, obesity, or both. In another meta-analysis of 10 studies on IL-6 and 9 studies on TNF-α, no statistically significant differences between patients with PCOS and appropriate controls were identified [ 34 ]. Aboeldalyl et al. conducted a large-scale meta-analysis of 63 articles and verified that CRP is moderately increased in patients with PCOS, and this result was also reported in a further evaluation of nonobese women with PCOS. They further conducted a meta-analysis of articles on IL-6 expression and reported a significant difference between patients with PCOS and controls. However, no significant difference was identified in a meta-analysis of articles on TNF-α [ 35 ]. CRP is produced in the liver as an acute phase protein in response to the release of IL-6 by macrophages or adipocytes [ 86 , 87 ], and the serum level of IL-6 is associated with long-term health risks in women with obesity and type-2 diabetes mellitus [ 41 , 88 ]. Although the literature findings regarding the expression of IL-6 and TNF-α are still controversial, restrictive, and inconsistent, the status of IL-6 as a major mediator for modulating CRP synthesis and its increased levels in patients with PCOS suggest the occurrence of interactions involving IL-6 and TNF-α. Collectively, these data suggest that CRP is a key factor that indicates the chronic inflammatory status of patients with PCOS. CRP participates in the development and maintenance of pain perception and can modulate pain sensitivity by influencing the pain threshold, thereby contributing to chronic pain [ 89 ]. An increased level of CRP is associated with the development of several pain conditions (e.g., fibromyalgia, lower back pain, pain involving opioid consumption following laparoscopic abdominal surgery, acute sciatic pain, and rheumatoid arthritis-related pain) [ 90 , 91 , 92 , 93 , 94 ]. CRP expression is also correlated with psychosocial stress, unhealthy behaviors, and sleep disorders [ 95 ]. Because patients with PCOS exhibit the pathological conditions of abnormal CRP level and chronic inflammation status, they may experience increased pain expression. However, the relationship between PCOS and these conditions requires further research to clarify. An increasing body of evidence is indicating that reactive oxygen species (ROS), which are overproduced and increase the oxidative stress in patients with PCOS, are involved in PCOS pathogenesis [ 96 , 97 ]. Elevated ROS levels cause mitochondrial dysfunction; thus, redox potential and oxidative stress levels lead to impaired cumulus cells in the ovaries of patients with PCOS [ 98 ], thereby exacerbating disease progression. ROS are also associated with pain development and maintenance [ 99 ]; the accumulation of oxidative stress in DRG neurons is a significant inducer of hyperalgesia, which results in chronic pain [ 100 ]. Increased levels of ROS in the spinal cord can promote pain perception by reducing γ-aminobutyric-acid-mediated inhibitory neuronal transmission, which increases the expression of neuropathic pain [ 101 ]. In addition, ROS accumulation is involved in visceral pain-related amygdala plasticity; thus, the administration of ROS scavengers may provide pain relief [ 102 ]. Because patients with PCOS exhibit increased pain prevalence and ROS levels, the accumulation of ROS may be a factor that promotes pain development or maintenance. IR is a prevalent symptom of PCOS that results from hyperandrogenism and the increased inflammatory status derived from the presence of reactive macrophages [ 42 ]. Thus, IR-related inflammatory processes are highly correlated and may stimulate each other [ 103 ]. The key pathological features of PCOS, such as obesity, IR, hyperandrogenism, and chronic inflammation [ 46 ], are highly correlated. However, the potential of IR to induce pain is still controversial. The relationship between IR and chronic pain has been established [ 104 ], and obesity can also increase the prevalence of chronic pain [ 105 , 106 ]. IR is also associated with fibromyalgia syndrome [ 107 ]; this pathophysiology was reported in a population of patients with PCOS who exhibited an increased frequency of fibromyalgia [ 108 ], which is a widespread pain anomaly characterized by a decreased pain threshold. A patient with fibromyalgia may experience musculoskeletal pain accompanied by an increased frequency of disorders pertaining to sleep, fatigue, mood, and memory. Animal model and human studies have reported that acid-sensing ion channel 3 (ASIC3) is predominantly expressed in the nociceptors in the body that modulate acid-evoked pain [ 109 ]. Notably, IR can impair the expression of ASIC3, thereby inducing neuropathic pain in rat models [ 110 , 111 ]. In particular, metformin, a main medication for type 2 diabetes with IR and PCOS [ 112 , 113 , 114 , 115 ], was reported to provide pain relief for chronic pain such as rheumatoid arthritis, neuropathic pain, and fibromyalgia [ 116 ]. A report on PCOS further indicated that metformin can increase the pain threshold of lean patients with PCOS [ 28 ]. These data suggest that for patients with PCOS, IR may be a risk factor for pain expression that may further exacerbate pain development.

This review summarized the current literature on pain perception in the context of PCOS, and the HRQoL findings obtained through the SF-36 indicate that patients with PCOS exhibit increased pain perception. Several PCOS-related pathologic factors may exacerbate pain perception, including low-grade inflammation, oxidative stress, adipogenesis, and IR. However, the questionnaire-based literature has only focused on rating pain and has not evaluated the various dimensions of pain expression such as pain type, potential causes, location, frequency, and pain scores. Thus, the association between pain expression and PCOS is still unclear. In particular, pain expression may be dynamic and diverse in patients with PCOS, and several diseases that cause bodily pain have been identified to be associated with PCOS. For instance, endometriosis and PCOS are both associated with pelvic pain [ 117 , 118 , 119 ]; they also have similar pathological causes (e.g., obesity and oxidative stress) and contribute to the increased risk of cancer development in the endometrium [ 120 , 121 ]. Sexual difficulties resulting from pain during intercourse are another major complaint of patients with PCOS [ 122 , 123 , 124 ], and they are typical symptoms of endometriosis. Relative to healthy individuals, patients with PCOS are more likely to develop chronic-pain-related and neuropathic-pain-related conditions such as migraine [ 27 ], fibromyalgia [ 107 ], rheumatoid arthritis [ 125 ], and irritable bowel syndrome [ 126 , 127 , 128 ]; thus, PCOS is a potential risk factor for the increased prevalence of pain-related conditions. However, the current HRQoL survey formats are limited in their ability to obtain comprehensive information regarding the pain perception of patients with PCOS. Even the survey specifically designed for patients with PCOS, namely the PCOS health-related quality-of-life questionnaire (i.e., PCOSQ), also excludes pain perception [ 129 ]. Consequently, the association between pain expression and PCOS remains unclear, and further research is required to determine whether PCOS is correlated with or causes pain expression. Furthermore, whether the pathophysiology of PCOS pertaining to low-grade inflammation, hyperandrogenism, and IR contributes to pain development and maintenance remains unclear, and further studies are necessary to clarify this topic. Notably, an increasing body of evidence is suggesting that mental status is associated with pain perception and that this association can be bidirectional (i.e., mental status and pain perception function as risk factors and comorbidities for each other) [ 130 , 131 , 132 , 133 ]. Mental disorders may increase the severity of pain, whereas prolonged periods of pain contribute to the increased severity of mental disorders involving fear, stress, depression, and anxiety. Numerous HRQoL surveys have characterized mental disorders as a dominant aspect of the lives of patients with PCOS [ 16 , 17 , 18 , 20 , 22 , 23 , 24 , 25 , 26 , 134 ] and a factor that may affect their pain perception. However, the association between pain and mental disorders in patients with PCOS requires further clarification. A questionnaire-based survey can only provide limited information about how PCOS affects mental status. The bilateral link between physical problems and mental disorders must be further studied to identify the relevant psychological factors and improve the health care provided to patients with PCOS. In the future, HRQoL surveys designed for patients with PCOS should include a detailed pain assessment that helps to clarify the possible causes of pain and the effects of pain on the lives of these patients, thereby helping clinicians to understand the underlying problems associated with PCOS and to develop improved strategies for health care and disease treatment. In clinics, gynecologists may be the first line who can care for and diagnose PCOS patients with abnormal pain perception—considering the susceptibility, carefully examining the source of the patient’s pain development, and evaluating the time and level of the patient’s pain perception. As early as detecting and relieving the patient’s abnormal pain perception is essential to improve the patient’s life quality. Active referral to other symptom-related clinicians is critical if the source of pain is beyond the gynecological expertise. Furthermore, basic studies should be conducted to clarify the pathological risk factors for pain in the context of PCOS; their focus should be on identifying and examining the key molecular and biological mechanisms. A model that incorporates both behavioral outcomes and molecular assessments is necessary to clarify the relationships and pathological mechanisms that link pain and PCOS. A clearer understanding of the causes of PCOS-associated symptoms can provide more insight into PCOS pathophysiology and contribute to the development of improved therapeutic approaches.

Polycystic ovary syndrome (PCOS) is the most common form of infertility disorder; its prevalence is estimated to be approximately 4% to 20% in women of reproductive age, and it accounts for 40% of female infertility cases [ 1 , 2 ]. PCOS also contributes to approximately 80% of anovulatory infertility cases [ 3 ]. The clinical implications of PCOS are heterogenous across reproductive and metabolic disorders resulting from endocrine disorders such as anovulation, hyperandrogenism, obesity, insulin resistance, type 2 diabetes mellitus, hypertension, cardiovascular diseases, dyslipidemia, hirsutism, and acne [ 4 ]. Because of the hormonal anomaly associated with PCOS, the skin of patients with partial PCOS may darken and form light brown or black patches. In addition, PCOS can increase patient risk for endometrial hyperplasia and uterine cancer [ 5 ]. Approximately 60% to 80% of patients with PCOS develop hyperandrogenism, androgen hyperactivation–induced ovulation disorder, adipogenesis, or insulin resistance (IR), which are the leading causes of PCOS symptoms [ 6 ]. In addition, the whole ovary of patients with PCOS may develop multiple antral follicles (AFCs) measuring 2 to 9 mm in diameter and/or an enlarged ovary measuring >10 mL. Excessive AFC development causes estrogen levels to increase, which in turn inhibits the secretion of follicle-stimulating hormones (FSHs), resulting in anovulation, prolongment of the menstrual cycle, and increased testosterone levels [ 7 ]. In addition, hyperandrogenism may increase adipogenesis and the production of serum-free fatty acids, leading to IR in PCOS pathophysiology. An excessive number of adipocytes can further release inflammation cytokines in the serum, thereby increasing IR manifestation in patients with PCOS [ 8 ]. However, the clinical symptoms of PCOS are heterogenous and may be associated with genetic disorders, environmental factors, and individual lifestyle factors, and the etiology and diagnostic criteria for PCOS are still being debated [ 9 , 10 , 11 ]. Health-related quality of life (HRQoL) is a general and dynamic concept that evaluates the effect of a disease or its related treatment on mental, physical, emotional, and social activities according to personal life perceptions [ 12 ]. It can represent an individual’s general status with respect to life satisfaction and quality. In the context of PCOS, PCOS-induced symptoms can considerably reduce a patient’s quality of life; therefore, PCOS-specific HRQoL assessments can be performed by administering direct patient questionnaires to obtain information that provides clinical management insights relating to the evaluation of physical, mental, and social therapies. In a self-report survey of patients with PCOS, the 36-item Short-Form Health Survey (SF-36) was used to evaluate HRQoL [ 13 ]. The SF-36 is the most used and well-established questionnaire, and it has been extensively applied to evaluate mental and physical status associated with various medical conditions [ 14 ]. It comprises eight evaluation dimensions, including physical components such as physical functioning, role limitations due to physical problems, bodily pain, and general health perceptions; it also incorporates mental components such as social functioning, mental health, and energy/vitality and role limitations due to emotional problems. SF-36 questionnaires are scored from 0 to 100, and a higher score indicates a higher quality of life. Notably, in 2017, Martin et al. conducted semi-structured interviews and reported that pain- and discomfort-related symptoms were the most common complaints among patients with PCOS, accounting for 27.6% of the complaints made by all interviewed patients [ 15 ]. Further, HRQoL-based studies and systematic reviews are increasingly indicating that bodily pain expression is significantly elevated in patients with PCOS [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ]. Although the symptoms of PCOS related to hyperandrogenism, metabolism, and reproductive function are heterogeneous and well-established, the symptoms involving bodily pain are still a topic of debate. Clinicians often overlook the pain perception of patients with PCOS, and they regard it as a PCOS symptom only during diagnosis and clinical management processes. Accordingly, understanding PCOS-specific outcomes and how PCOS symptoms affect the lives of patients is valuable to the development of clinical diagnoses and treatments related to PCOS.